{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:49:25Z","timestamp":1778143765668,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and purpose<\/jats:title>\n                <jats:p>To gain insight into the treatment outcomes for anal cancer a retrospective analysis was performed with a special emphasis on trends in outcome and toxicities over time and on treatment of elderly patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Medical records of 98 consecutive patients with squamous cell carcinoma of the anus of all stages treated with curative intent between 01-01-2009 and 31-12-2018 were analyzed with follow up until 31-12-2020. Standard tumor and pathological lymph node dose were 59.4\u00a0Gy (median 59.4\u00a0Gy, range 59.4\u201370\u00a0Gy) or 60\u00a0Gy (no deviation from intended dose), elective nodal regions were treated with 45\u00a0Gy (no deviations). Radiotherapy techniques in this period evolved from 3D-conformal to IMRT and VMAT. In 23 patients electron beams were used.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Median age was 63\u00a0years (range 41\u201388), the majority of patients were female (60%). Twenty three patients were\u2009&gt;\u200975\u00a0years old. The TNM stages were I, II, IIIA, and IIIB in 18%, 40%, 15% and 27%, 58% of patients had N0 status. Concurrent mitomycin C and 5-fluoruracil-based chemotherapy was given in 63 patients (64%). Five-year overall survival (OS), disease free survival (DFS), locoregional control (LRC) and colostomy free survival (CFS) were 71%, 80%, 82%, and 82% for the whole group. Results in patients\u2009&gt;\u200975\u00a0years of age were not statistically different from those in younger patients. With the introduction of more conformal techniques DFS did not change and toxicities decreased.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Real word treatment outcomes per disease stage were in line with what is reported in literature. Older patients should also be offered treatment with curative intent.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-022-02049-8","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T15:03:33Z","timestamp":1650467013000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment results for patients with squamous-cell carcinoma of the anus, a single institution retrospective analysis"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3506-4966","authenticated-orcid":false,"given":"Karen J.","family":"Neelis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Django M.","family":"Kip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank M.","family":"Speetjens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvette M.","family":"van der Linden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"2049_CR1","unstructured":"IKNL. Nederlandse Kankerregistratie (NKR). retrieved via iknlnl\/nkr-cijfers March 31, 2021."},{"issue":"6","key":"2049_CR2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","volume":"14","author":"RD James","year":"2013","unstructured":"James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol. 2013;14(6):516\u201324.","journal-title":"Lancet Oncol"},{"issue":"35","key":"2049_CR3","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","volume":"30","author":"LL Gunderson","year":"2012","unstructured":"Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB 3rd, et al. Long-term update of US GI intergroup RTOG 98\u201311 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin. J Clin Oncol. 2012;30(35):4344\u201351.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2049_CR4","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"H Bartelink","year":"1997","unstructured":"Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15(5):2040\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2049_CR5","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0360-3016(03)00417-6","volume":"56","author":"E Deniaud-Alexandre","year":"2003","unstructured":"Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Houry S, Gallot D, et al. Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal. Int J Radiat Oncol Biol Phys. 2003;56(5):1259\u201373.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2049_CR6","doi-asserted-by":"crossref","unstructured":"de Meric de Bellefon M, Lemanski C, Castan F, Samalin E, Mazard T, Lenglet A, et al. Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure. Radiother Oncol. 2020;144:141\u20137.","DOI":"10.1016\/j.radonc.2019.11.016"},{"issue":"2","key":"2049_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.adro.2017.01.009","volume":"2","author":"D Mitra","year":"2017","unstructured":"Mitra D, Hong TS, Horick N, Rose B, Drapek LN, Blaszkowsky LS, et al. Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. Adv Radiat Oncol. 2017;2(2):110\u20137.","journal-title":"Adv Radiat Oncol"},{"key":"2049_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/1748-717X-9-113","volume":"9","author":"SA Koerber","year":"2014","unstructured":"Koerber SA, Slynko A, Haefner MF, Krug D, Schoneweg C, Kessel K, et al. Efficacy and toxicity of chemoradiation in patients with anal cancer\u2013a retrospective analysis. Radiat Oncol. 2014;9:113.","journal-title":"Radiat Oncol"},{"issue":"3","key":"2049_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1308\/rcsann.2018.0202","volume":"101","author":"A Ghareeb","year":"2019","unstructured":"Ghareeb A, Paramasevon K, Mokool P, van der Voet H, Jha M. Toxicity and survival of anal cancer patients treated with intensity-modulated radiation therapy. Ann R Coll Surg Engl. 2019;101(3):168\u201375.","journal-title":"Ann R Coll Surg Engl"},{"issue":"11","key":"2049_CR10","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1080\/0284186X.2018.1503713","volume":"57","author":"YB Pan","year":"2018","unstructured":"Pan YB, Maeda Y, Wilson A, Glynne-Jones R, Vaizey CJ. Late gastrointestinal toxicity after radiotherapy for anal cancer: a systematic literature review. Acta Oncol. 2018;57(11):1427\u201337.","journal-title":"Acta Oncol"},{"issue":"1","key":"2049_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ijrobp.2010.09.030","volume":"82","author":"LA Kachnic","year":"2012","unstructured":"Kachnic LA, Tsai HK, Coen JJ, Blaszkowsky LS, Hartshorn K, Kwak EL, et al. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys. 2012;82(1):153\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2049_CR12","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1016\/j.ijrobp.2012.12.008","volume":"85","author":"MJ Deenen","year":"2013","unstructured":"Deenen MJ, Dewit L, Boot H, Beijnen JH, Schellens JH, Cats A. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. Int J Radiat Oncol Biol Phys. 2013;85(5):e201\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2049_CR13","unstructured":"TNM classification of malignant tumours, 7th edition ed. Cancer UIUA, editor: Wiley; 2009."},{"issue":"16","key":"2049_CR14","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","volume":"299","author":"JA Ajani","year":"2008","unstructured":"Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299(16):1914\u201321.","journal-title":"JAMA"},{"issue":"11","key":"2049_CR15","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","volume":"19","author":"LM Henricks","year":"2018","unstructured":"Henricks LM, Lunenburg C, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018;19(11):1459\u201367.","journal-title":"Lancet Oncol"},{"issue":"12","key":"2049_CR16","first-page":"4705","volume":"6","author":"AB van Kuilenburg","year":"2000","unstructured":"van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6(12):4705\u201312.","journal-title":"Clin Cancer Res"},{"key":"2049_CR17","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, June 2010. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf."},{"issue":"7","key":"2049_CR18","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","volume":"102","author":"J Northover","year":"2010","unstructured":"Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010;102(7):1123\u20138.","journal-title":"Br J Cancer"},{"issue":"16","key":"2049_CR19","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","volume":"30","author":"D Peiffert","year":"2012","unstructured":"Peiffert D, Tournier-Rangeard L, Gerard JP, Lemanski C, Francois E, Giovannini M, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012;30(16):1941\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2049_CR20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/COC.0000000000000673","volume":"43","author":"ML Frazer","year":"2020","unstructured":"Frazer ML, Yang G, Felder S, McDonald J, Sanchez J, Dessureault S, et al. Determining optimal follow-up for patients with anal cancer following chemoradiation. Am J Clin Oncol. 2020;43(5):319\u201324.","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"2049_CR21","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.radonc.2014.04.013","volume":"111","author":"R Glynne-Jones","year":"2014","unstructured":"Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol. 2014;111(3):330\u20139.","journal-title":"Radiother Oncol"},{"issue":"1","key":"2049_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/0284186X.2016.1244356","volume":"56","author":"JE Dale","year":"2017","unstructured":"Dale JE, Sebj\u00f8rnsen S, Leh S, R\u00f6sler C, Aaserud S, M\u00f8ller B, et al. Multimodal therapy is feasible in elderly anal cancer patients. Acta Oncol. 2017;56(1):81\u20137.","journal-title":"Acta Oncol"},{"issue":"11","key":"2049_CR23","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00066-015-0885-4","volume":"191","author":"C Henkenberens","year":"2015","unstructured":"Henkenberens C, Meinecke D, Michael S, Bremer M, Christiansen H. Reduced radiation dose for elective nodal irradiation in node-negative anal cancer: back to the roots? Strahlenther Onkol. 2015;191(11):845\u201354.","journal-title":"Strahlenther Onkol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02049-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-022-02049-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02049-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T14:14:38Z","timestamp":1650550478000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-022-02049-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2049"],"URL":"https:\/\/doi.org\/10.1186\/s13014-022-02049-8","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]},"assertion":[{"value":"21 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol for our study was submitted for review to the LUMC ethics committee (G20.026, March 11, 2020) and was deemed not necessary to be subjected to further review under the Medical Research Involving Human Subjects Act (WMO). As such individual patient consent was not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}